Leerink Partners Lowers PROCEPT BioRobotics (NASDAQ:PRCT) Price Target to $30.00

PROCEPT BioRobotics (NASDAQ:PRCT) had its target price dropped by stock analysts at Leerink Partners from $55.00 to $30.00 in a note issued to investors on Thursday,Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Leerink Partners’ target price points to a potential upside of 32.22% from the company’s current price.

Several other brokerages also recently commented on PRCT. Truist Financial dropped their price objective on PROCEPT BioRobotics from $50.00 to $47.00 and set a “buy” rating on the stock in a research note on Thursday, December 18th. Wall Street Zen upgraded PROCEPT BioRobotics from a “sell” rating to a “hold” rating in a report on Saturday, January 10th. Oppenheimer reaffirmed a “market perform” rating on shares of PROCEPT BioRobotics in a research report on Thursday. TD Cowen cut their price objective on PROCEPT BioRobotics from $50.00 to $34.00 and set a “buy” rating on the stock in a report on Thursday. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of PROCEPT BioRobotics in a research note on Thursday, January 22nd. Eight analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, PROCEPT BioRobotics has an average rating of “Hold” and a consensus target price of $41.90.

PROCEPT BioRobotics Stock Down 4.0%

PROCEPT BioRobotics stock opened at $22.69 on Thursday. The firm has a market capitalization of $1.27 billion, a price-to-earnings ratio of -13.27 and a beta of 0.99. The company’s 50 day simple moving average is $30.00 and its 200 day simple moving average is $33.53. The company has a debt-to-equity ratio of 0.14, a current ratio of 8.44 and a quick ratio of 7.20. PROCEPT BioRobotics has a fifty-two week low of $19.35 and a fifty-two week high of $66.85.

PROCEPT BioRobotics (NASDAQ:PRCT) last issued its earnings results on Wednesday, February 25th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.21). The firm had revenue of $76.38 million during the quarter, compared to the consensus estimate of $93.70 million. PROCEPT BioRobotics had a negative net margin of 31.02% and a negative return on equity of 24.82%. The firm’s revenue for the quarter was up 11.9% on a year-over-year basis. During the same period in the previous year, the company posted ($0.35) EPS. As a group, sell-side analysts anticipate that PROCEPT BioRobotics will post -1.75 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Vega Investment Solutions grew its holdings in shares of PROCEPT BioRobotics by 52.0% during the second quarter. Vega Investment Solutions now owns 775 shares of the company’s stock worth $45,000 after buying an additional 265 shares in the last quarter. JTC Employer Solutions Trustee Ltd acquired a new position in PROCEPT BioRobotics during the 3rd quarter worth approximately $30,000. Caitong International Asset Management Co. Ltd grew its stake in shares of PROCEPT BioRobotics by 436.3% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 917 shares of the company’s stock worth $29,000 after acquiring an additional 746 shares in the last quarter. AlphaQuest LLC grew its stake in shares of PROCEPT BioRobotics by 1,262.5% during the 2nd quarter. AlphaQuest LLC now owns 1,090 shares of the company’s stock worth $63,000 after acquiring an additional 1,010 shares in the last quarter. Finally, CWM LLC raised its holdings in shares of PROCEPT BioRobotics by 40.7% in the second quarter. CWM LLC now owns 1,228 shares of the company’s stock valued at $71,000 after purchasing an additional 355 shares during the last quarter. 89.46% of the stock is owned by institutional investors and hedge funds.

PROCEPT BioRobotics News Roundup

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Positive Sentiment: Company outlined a multi‑year plan and issued 2026 guidance of $390M–$410M, signaling a path to higher revenue as it pursues pricing discipline and commercial realignment; the investor day attempted to frame a roadmap to sustainable growth. PROCEPT outlines $390M–$410M revenue target for 2026
• Positive Sentiment: Certain sell‑side firms maintained constructive ratings (buy/overweight/outperform) even after trimming targets, which leaves upside scenarios if execution and revenue recovery accelerate. Analyst updates (summary)
• Neutral Sentiment: Q4 results showed revenue grew ~11.9% YoY and gross profit improved, and operating and net losses narrowed versus a year ago — a mixed quarter that demonstrates progress but also falling short of market expectations. Q4 earnings highlights
• Neutral Sentiment: Investor‑day materials and the earnings call transcript provide detail on assumptions behind guidance and the commercial reset; these are useful for modeling recovery timing but don’t eliminate execution risk. Investor Day slideshow
• Negative Sentiment: EPS and revenue missed consensus (EPS -$0.53 vs. -$0.32 estimate; revenue below forecasts), which triggered immediate downward pressure as investors re‑priced near‑term growth expectations. Q4 miss coverage
• Negative Sentiment: Several analysts cut price targets and/or downgraded the stock (examples: Jefferies to Hold; BofA to Underperform with $20 PT; Leerink, TD Cowen and Piper lowered targets), increasing short‑term downside risk and contributing to weaker sentiment. Analyst downgrades and price target changes
• Negative Sentiment: A securities‑fraud investigation by Ademi LLP into PROCEPT’s disclosures emerged, adding legal and headline risk that can prolong volatility and deter risk‑tolerant buyers. Ademi LLP investigation notice
• Negative Sentiment: Shares reached a new 52‑week low and traded at elevated volumes around these announcements, reflecting broad selling pressure and a reassessment of near‑term execution and guidance credibility. 52-week low coverage

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.